Anavex Life Sciences (AVXL) Capital Expenditures (2013 - 2014)

Anavex Life Sciences (AVXL) reported Capital Expenditures of $688.0 for Q3 2014, down 70.43% sequentially from $2327.0 in Q4 2013.

Anavex Life Sciences (AVXL) Capital Expenditures (2013 - 2014) Analysis & Trends

Anavex Life Sciences (AVXL) has 2 years of Capital Expenditures data on file, last reported at $688.0 in Q3 2014.

For the quarter ending Q3 2014, Capital Expenditures changed N/A year-over-year to $688.0; the trailing twelve-month figure through Jun 2015 stood at $688.0 (down 70.43% YoY), and the FY2014 full-year result was $3015.0, changed N/A from the prior year.
Capital Expenditures eased to $688.0 in Q3 2014, from $2327.0 in the prior quarter.
In the past five years, Capital Expenditures ranged from a high of $2327.0 in Q4 2013 to a low of $688.0 in Q3 2014.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capital Expenditures (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-8,939.03
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	43.25 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	133.40 Mn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	230.60 Mn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	786,000.00
10	Anavex Life Sciences	229.83 Mn	98.08 Mn	-	-

Download Data